1. Scrip
  2. >>Business
  3. >>Strategy

EQRx Confronts US Drug Development Realities, Shifts Pricing Approach

Company’s $1.5bn To Last Into 2028

 
• By Mandy Jackson

Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.

Red paper plane is different from the white paper plane. business and leadership concept. airplane change direction.
The drug pricing strategy for EQRx's first two products in the US will differ from elsewhere in the world • Source: Shutterstock

EQRx, Inc. says it remains committed to making its drug candidates accessible to patients, but the company’s stated purpose of making its therapies available at the lowest possible prices is turning out to be more challenging than it thought. EQRx announced it is ending US development of its PD-1 inhibitor sugemalimab and significantly delaying the launch of its EGFR inhibitor aumolertinib.

The company also said during its third quarter financial and strategic update on 10 November that aumolertinib and CDK4/6 inhibitor lerociclib will launch in the US at market-based

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.